Insiders · BEAM

Mark Fishman

Director at Beam Therapeutics Inc. (BEAM)

Mark Fishman has filed 6 insider reports with the SEC since June 2021, as director at Beam Therapeutics Inc. (BEAM). The latest filing, on June 5, 2026, reports grant or award at Beam Therapeutics Inc. (BEAM).

Filings
6
Companies
1
Bought on market
None
Sold on market
None

Companies where Mark Fishman is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Beam Therapeutics Inc. logo
BEAM
Beam Therapeutics Inc.
Director$20.94Jun 5, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark Fishman with

Other insiders at the same companies

Questions about Mark Fishman

What is Mark Fishman's role at Beam Therapeutics Inc.?
Mark Fishman reports to the SEC as director at Beam Therapeutics Inc. (BEAM), according to the latest filing on June 5, 2026.
Has Mark Fishman bought or sold stock recently?
No open-market purchases or sales by Mark Fishman are on file. The filings report grant or award.
How do I get alerts when Mark Fishman files?
Follow Mark Fishman on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark Fishman (SEC CIK 0001786003). Totals count each trade once, skipping amendments whose original is on file, from Jun 14, 2021 on. View on SEC EDGAR · Get this as JSON